One‐year outcome from an all‐comers population of patients with ST‐segment elevation myocardial infarction treated with biolimus‐eluting stent with biodegradable polymer

Abstract

In a real-world cohort of STEMI patients undergoing PCI, the use of BES is associated with good 1-year clinical outcome. These results confirm and expand previous findings showing the efficacy and safety of BES in the setting of randomized trials.

Angiographic and clinical performance of polymer‐free biolimus‐eluting stent in patients with ST‐segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study

“…The Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare‐Metal Stents in Acute ST‐Elevation Myocardial Infarction (COMFORTABLE AMI) trial involving 1161 patients subsequently showed for biodegradable‐polymer BES a lower risk of the 1 year composite primary endpoint of cardiac death, target‐vessel MI, and TLR (4.3% vs 8.7%, P = 0.004) . These findings were further supported in a real‐world multicenter registry of 311 patients showing a 3.4% rate of MACE (composite of cardiac death, recurrent MI, and ischemia‐driven TVR) at 1 year follow‐up .…”

Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study)

“… 23 Among patients with ST-segment-elevation MI undergoing primary PCI, BES was as sociated with a low incidence of 1-year MACE (3.2%) and also continued to improve cardiovascular events, compared with BMS beyond 1 year. 24 25 AMI subgroup analysis of the LEADER trial also showed BES, compared with SES, significantly improved 5-year safety and efficacy outcomes in patients with AMI (18.2% vs. 25.9%, p =0.025). 26 Our study will extend the follow-up period of the enrolled patients to 5 years to assess the long-term clinical outcomes of BES in Korean patients with ACS.…”

Safety and efficacy profile of bioresorbable‐polylactide‐polymer‐biolimus‐A9‐eluting stents versus durable‐polymer‐everolimus‐ and zotarolimus‐eluting stents in patients with acute coronary syndrome

“…Only some small studies compared new‐generation BES versus EES/ZES. For instance, Tomai et al noticed that BES was associated with a good 1‐year clinical outcome in a real‐world STEMI cohort . Adriaenssens et al in their small preliminary series demonstrated no difference in the incidence of ST and overall MACE at 9‐months despite the significantly higher percentage of uncovered struts after bioresorbable‐polymer‐BES versus EES as assessed by OCT in the setting of ACS .…”